Stockscreener 앱 받기
4.49
2.51%
0.11
전일 마감가:
$4.38
열려 있는:
$4.39
하루 거래량:
2.32M
Relative Volume:
0.78
시가총액:
$577.72M
수익:
-
순이익/손실:
$-110.78M
주가수익비율:
-5.1609
EPS:
-0.87
순현금흐름:
$-75.59M
1주 성능:
-7.14%
1개월 성능:
-18.07%
6개월 성능:
-40.61%
1년 성능:
+76.08%
1일 변동 폭
$4.33
$4.52
1주일 범위
$4.15
$4.84
52주 변동 폭
$2.43
$9.97
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
HUMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| HUMA | 4.49 | 577.72M | 0 | -110.78M | -75.59M | -0.87 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Humacyte, Inc. Shareholder Alert: Robbins LLP Reminds Investors of the HUMA Securities Class Action - GlobeNewswire
Humacyte, Inc. Shareholder Alert: Robbins LLP Reminds Investors of the HUMA Securities Class Action - GlobeNewswire Inc.
HUMA DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before January 17, 2025 - The Globe and Mail
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead - The Bakersfield Californian
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 – HUMA - Morningstar
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH) - The Manila Times
Humacyte sees success in dual emergency-engineered tissue trials - Yahoo Finance
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders - Marketscreener.com
HUMA Deadline to Lead in Securities Fraud Lawsuit is January 17, 2025Contact Kaplan Fox & Kilsheimer LLP - The Globe and Mail
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Morningstar
Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues – Hagens Berman - GlobeNewswire
Humacyte director Brady Dougan buys $7,978 in common stock - Investing.com India
ROSEN, LEADING INVESTOR COUNSEL, Encourages Humacyte, Inc. - GlobeNewswire
HUMACYTE, INC. (NASDAQ: HUMA) INVESTOR ALERT: Investors - GlobeNewswire
Insider Buyers At Humacyte Likely Disappointed With 17% Slide - Yahoo Finance
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
HUMA INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $00,000 In HUMA To Contact Him Directly To Discuss Their Options - PR Newswire
Humacyte announces publication of results on ATEV - TipRanks
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery - The Manila Times
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial - EIN News
Humacyte CEO Laura Niklason buys shares worth $7,978 - Investing.com
Humacyte CEO Laura Niklason buys shares worth $7,978 By Investing.com - Investing.com UK
Humacyte director Brady Dougan buys $7,978 in common stock By Investing.com - Investing.com UK
Humacyte CEO Laura Niklason sells $6.6m in common stock By Investing.com - Investing.com Nigeria
Humacyte CEO Laura Niklason sells $6.6m in common stock - Investing.com India
Humacyte director Brady Dougan sells shares worth $6.6 million By Investing.com - Investing.com Nigeria
Humacyte director Brady Dougan sells shares worth $6.6 million - Investing.com
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Humacyte, Inc. (HUMA) - EIN News
HUMA LAWSUIT ALERT: Levi & Korsinsky LLP Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - TipRanks
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors - Business Wire
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Blood Vessel Maker Faces Investor Suit Over FDA Findings - Law360
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Humacyte, Inc. - PR Newswire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors - Business Wire
Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights - The Bakersfield Californian
Humacyte Faces Financial Uncertainty: Potential Impact on Share Price and Capital - MSN
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Shareholder lawsuit shines light on biotech's FDA woes - The Business Journals
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues– Hagens Berman - GlobeNewswire
HUMA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Humacyte, Inc. - Business Wire
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024 - The Manila Times
Humacyte, Inc. Presents Preclinical Results of Small-Diameter ATEV?? for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024 - Marketscreener.com
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - GlobeNewswire
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):